We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 05, 2015

ADT With and Without Docetaxel and Estramustine for High-Risk Localized Prostate Cancer

The Lancet Oncology


Additional Info

The Lancet Oncology
Androgen Deprivation Therapy Plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-Risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial
Lancet Oncol 2015 May 28;[EPub Ahead of Print], K Fizazi, L Faivre, F Lesaunier, R Delva, G Gravis, F Rolland, F Priou, JM Ferrero, N Houede, L Mourey, C Theodore, I Krakowski, JF Berdah, M Baciuchka, B Laguerre, A Fléchon, A Ravaud, I Cojean-Zelek, S Oudard, JL Labourey, P Chinet-Charrot, E Legouffe, JL Lagrange, C Linassier, G Deplanque, P Beuzeboc, JL Davin, AL Martin, M Habibian, A Laplanche, S Culine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading